Synonyms: Sophoretin,Meletin,Quercetine,Xanthaurine,Quercetol,Quercitin,Quertine,Flavin meletin
IUPAC Name:
2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one,
Functional Activity:
Inhibitors of mitochondrial ATPase, phosphodiesterase (PDE), PI3-kinase (PI3K) and protein kinase C (PKC).
Technical Data:
M.Wt: 338.27
Formula: C15H107.2H2O
Solubility: Soluble to 100 mM in DMSO
Purity: >99%
Storage: -20°C
CAS No.: 6151-25-3
Related Products by Target:
References for Quercetin:
1. Yu, Z. J., He, L. Y., Chen, Y., Wu, M. Y., Zhao, X. H., and Wang, Z. Y. [Effects of quercetin on the expression of VEGF-C and VEGFR-3 in human cancer MGC-803 cells]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 25: 678-680, 2009.
2. Seufi, A. M., Ibrahim, S. S., Elmaghraby, T. K., and Hafez, E. E. Preventive effect of the flavonoid, quercetin, on hepatic cancer in rats via oxidant/antioxidant activity: molecular and histological evidences. J Exp Clin Cancer Res, 28: 80, 2009.
3. Shan, B. E., Wang, M. X., and Li, R. Q. Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway. Cancer Invest, 27: 604-612, 2009.
4. Jagtap, S., Meganathan, K., Wagh, V., Winkler, J., Hescheler, J., and Sachinidis, A. Chemoprotective mechanism of the natural compounds, epigallocatechin-3-O-gallate, quercetin and curcumin against cancer and cardiovascular diseases. Curr Med Chem, 16: 1451-1462, 2009.
5. Xavier, C. P., Lima, C. F., Preto, A., Seruca, R., Fernandes-Ferreira, M., and Pereira-Wilson, C. Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells. Cancer Lett, 281: 162-170, 2009.
6. Lee, Y. K., Park, S. Y., Kim, Y. M., Lee, W. S., and Park, O. J. AMP kinase/cyclooxygenase-2 pathway regulates proliferation and apoptosis of cancer cells treated with quercetin. Exp Mol Med, 41: 201-207, 2009.
Certificate of Analysis/MSDS is available upon request with lot number
References for Omeprazole:
1. Freeman, K. L. and Trezevant, M. S. Interaction between liquid protein solution and omeprazole suspension. Am J Health Syst Pharm, 66: 1901-1902, 2009.
2. Fang, H. M., Xu, J. M., Mei, Q., Diao, L., Chen, M. L., Jin, J., and Xu, X. H. Involvement of cytochrome P450 3A4 and P-glycoprotein in first-pass intestinal extraction of omeprazole in rabbits. Acta Pharmacol Sin, 30: 1566-1572, 2009.
3. Haffey, M. B., Buckwalter, M., Zhang, P., Homolka, R., Martin, P., Lasseter, K. C., and Ermer, J. C. Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. Postgrad Med, 121: 11-19, 2009.
4. Panti, A., Bennett, R. C., Corletto, F., Brearley, J., Jeffery, N., and Mellanby, R. J. The effect of omeprazole on oesophageal pH in dogs during anaesthesia. J Small Anim Pract, 50: 540-544, 2009.
5. Cuisset, T., Frere, C., Quilici, J., Poyet, R., Gaborit, B., Bali, L., Brissy, O., Morange, P. E., Alessi, M. C., and Bonnet, J. L. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol, 54: 1149-1153, 2009.
6. Van Der Straeten, F., Al-Afandi, A., De Paepe, K., Bovy, J., and Plaizier-Vercammen, J. [Pharmacy compounding of an omeprazole suspension]. J Pharm Belg: 54-63, 2009.
Certificate of Analysis/MSDS is available upon request with lot number
References for Diltiazem:
1. Sultana, Y., Mall, S., Maurya, D. P., Kumar, D., and Das, M. Preparation and in vitro characterization of diltiazem hydrochloride loaded alginate microspheres. Pharm Dev Technol, 14: 321-331, 2009.
2. Demir, M., Ozaydin, M., Varol, E., Dogan, A., and Altinbas, A. Effects of metoprolol and diltiazem on plasma homocysteine levels in patients with isolated coronary artery ectasia. Anadolu Kardiyol Derg, 9: 69-70, 2009.
3. Ezeugo, U. and Glasser, S. P. Clinical benefits versus shortcomings of diltiazem once-daily in the chronotherapy of cardiovascular diseases. Expert Opin Pharmacother, 10: 485-491, 2009.
4. Rigat, B. and Mahuran, D. Diltiazem, a L-type Ca(2+) channel blocker, also acts as a pharmacological chaperone in Gaucher patient cells. Mol Genet Metab, 96: 225-232, 2009.
5. Matsumura, C. Y., Pertille, A., Albuquerque, T. C., Santo Neto, H., and Marques, M. J. Diltiazem and verapamil protect dystrophin-deficient muscle fibers of MDX mice from degeneration: a potential role in calcium buffering and sarcolemmal stability. Muscle Nerve, 39: 167-176, 2009.
6. Bertera, F. M., Mayer, M. A., Opezzo, J. A., Taira, C. A., and Hocht, C. Increased sensitivity to diltiazem hypotensive effect in an experimental model of high-renin hypertension. J Pharm Pharmacol, 61: 79-87, 2009.
7. Bojanic, V., Bojanic, Z., Najman, S., Savic, T., Jakovljevic, V., Najman, S., and Jancic, S. Diltiazem prevention of toxic effects of monosodium glutamate on ovaries in rats. Gen Physiol Biophys, 28 Spec No: 149-154, 2009.
Certificate of Analysis/MSDS is available upon request with lot number
References for Clotrimazole :
1. Parmar, P. and Mehta, A. Development and Validation of HPTLC Method for the Estimation of Clotrimazole in Bulk drug and Tablet Formulation. Indian J Pharm Sci, 71: 451-454, 2009.
2. Harish, N. M., Prabhu, P., Charyulu, R. N., Gulzar, M. A., and Subrahmanyam, E. V. Formulation and Evaluation of in situ Gels Containing Clotrimazole for Oral Candidiasis. Indian J Pharm Sci, 71: 421-427, 2009.
3. Sholapurkar, A. A., Pai, K. M., and Rao, S. Comparison of efficacy of fluconazole mouthrinse and clotrimazole mouthpaint in the treatment of oral candidiasis. Aust Dent J, 54: 341-346, 2009.
4. Iannelli, A., de Sousa, G., Zucchini, N., Peyre, L., Gugenheim, J., and Rahmani, R. Clotrimazole protects the liver against normothermic ischemia-reperfusion injury in rats. Transplant Proc, 41: 4099-4104, 2009.
5. Furrow, E. and Groman, R. P. Intranasal infusion of clotrimazole for the treatment of nasal aspergillosis in two cats. J Am Vet Med Assoc, 235: 1188-1193, 2009.
6. Rasouli, M. R., Rahimi-Movaghar, V., and Vaccaro, A. R. Re: Usul H, Arslan E, Cansever T, et al. Effects of clotrimazole on experimental spinal cord ischemia/reperfusion injury in rats. Spine 2008;33:2863-7. Spine (Phila Pa 1976), 34: 1884, 2009.
Certificate of Analysis/MSDS is available upon request with lot number
References for 8-Phenyltheophylline:
1. Murray, S., Odupitan, A. O., Murray, B. P., Boobis, A. R., and Edwards, R. J. Inhibition of human CYP1A2 activity in vitro by methylxanthines: potent competitive inhibition by 8-phenyltheophylline. Xenobiotica, 31: 135-151, 2001.
2. Lee, S. C., Mallet, R. T., Shizukuda, Y., Williams, A. G., Jr., and Downey, H. F. Canine coronary vasodepressor responses to hypoxia are attenuated but not abolished by 8-phenyltheophylline. Am J Physiol, 262: H955-960, 1992.
3. Sawynok, J., Espey, M. J., and Reid, A. 8-Phenyltheophylline reverses the antinociceptive action of morphine in the periaqueductal gray. Neuropharmacology, 30: 871-877, 1991.
4. Wei, H. M., Kang, Y. H., and Merrill, G. F. Canine coronary vasodepressor responses to hypoxia are abolished by 8-phenyltheophylline. Am J Physiol, 257: H1043-1048, 1989.
5. Wormald, A., Bowmer, C. J., Yates, M. S., and Collis, M. G. Pharmacokinetics of 8-phenyltheophylline in the rat. J Pharm Pharmacol, 41: 418-420, 1989.
6. Nicholson, C. D. and Wilke, R. 8-phenyltheophylline as an inhibitor of cyclic AMP hydrolysis by cyclic nucleotide phosphodiesterase. J Auton Pharmacol, 9: 159-165, 1989.